ESC Premium Access

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

Congress Session

About the speaker

Doctor Yanina Lenz

Berlin (Germany)
0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Speaker: Mr Q. Ying (Perth, AU)

Thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Thumbnail

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Doctor Y. Lenz, Mr A. Holt, Mr A. Holt, Mr Q. Ying, Doctor M. Delbeck...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

COVID-19 & digital health: is techcelleration here to stay? Let's discuss

22 October 2021

ESC Premium Access

COVID-19 & digital health: techcelleration here to stay?

22 October 2021

ESC Premium Access

The ESC journey and future directions.

22 October 2021

This platform is supported by

logo Novo Nordisk